866-997-4948(US-Canada Toll Free)

Tasquinimod (Prostate Cancer) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Dec 2012

Category :

Cancer

No. of Pages : 56 Pages


Tasquinimod (Prostate Cancer) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Tasquinimod (Prostate Cancer) Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Active Biotech and Ipsen’s tasquinimod is a small molecule that binds to the calcium-binding protein, S100A9, which modulates thrombospondin-1 expression and inhibitors tumor angiogenesis. It is in development as a first-line treatment for mildly symptomatic or asymptomatic CRPC with bone metastases. Tasquinimod is administered once daily.

Scope

  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Tasquinimod including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Tasquinimod for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Tasquinimod performance 
  • Obtain sales forecast for Tasquinimod from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Related Reports 9

3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 10
3.1.3 Prognosis 11
3.1.4 Quality of Life 12
3.2 Symptoms 13

4 Disease Management 14
4.1 Diagnosis and Referral Overview 14
4.2 Treatment Overview 16
4.2.1 Conservative Management Strategies 20
4.2.2 Localized Treatments 21
4.2.3 Hormone Therapy 22
4.2.4 Drug Therapies 24

5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27

6 Opportunity and Unmet Need 30
6.1 Overview 30
6.2 Efficacy at Prolonging Overall Survival 31
6.3 Safety 31
6.4 Mitigation of Symptoms 32
6.5 Cost 32
6.6 Convenient Routes of Administration 32
6.7 Accurate Diagnostic Tests and Surveillance Tools 33
6.8 Unmet Needs Gap Analysis 33
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 34
7 Pipeline Assessment 35
7.1 Overview 35
7.2 Promising Drugs in Clinical Development 36

8 Tasquinimod 38
8.1 Overview 38
8.2 Efficacy 39
8.3 Safety 39
8.4 Dosing and Formulation 39
8.5 Potential Clinical Positioning 40
8.6 Potential Commercial Positioning 40
8.7 Pricing and Reimbursement 40
8.8 SWOT Analysis 41
8.9 Forecast 42

9 Appendix 43
9.1 Bibliography 43
9.2 Abbreviations 47
9.3 Methodology 49
9.4 Forecasting Methodology 49
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 49
9.4.2 Percent Drug-treated Patients 50
9.4.3 Percent Hormone Therapy-Treated Patients 50
9.4.4 General Pricing Assumptions 50
9.4.5 Individual Drug Assumptions 52
9.4.6 Generic Erosion 53
9.4.7 Pricing of Pipeline Agents 53
9.5 Physicians and Specialists Included in This Study 53
9.6 Survey of Prescribing Physicians 54
9.7 About the Authors 54
9.7.1 Authors 54
9.7.2 Global Head of Healthcare 55
9.8 About GlobalData 56
9.9 Contact Us 56
9.10 Disclaimer 56

List of Table


Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 12
Table 2: Global Variations in Recommendations on Routine PSA Screening 14
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 17
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 19
Table 5: Leading Treatments for Prostate Cancer, 2012 29
Table 6: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment 30
Table 7: Overall Unmet Needs, CRPC - Current Level of Attainment 31
Table 8: Clinical Unmet Needs - Gap Analysis, 2012 34
Table 9: Prostate Cancer - Phase III Pipeline, 2012 36
Table 10: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 36
Table 11: Product Profile - Tasquinimod 38
Table 12: Tasquinimod SWOT Analysis, 2012 41
Table 13: Global Sales Forecasts ($m) for Tasquinimod, 2012-2022 42
Table 14: Physicians Surveyed, By Country 54

List of Chart


Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 18
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *